TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Shea Nut Oil in Hemophilic Arthropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 20 years and above~* hemophilia A or B patients who reported painful (VAS ≥ 3) hemophilic arthropathy in ankles, elbows or knees for at least 6 months.~Exclusion Criteria:~* presence of joint infections~* any surgery on the joint in preceding 6 months~* intra-articular HA injection within the past 6 months~* history of rheumatoid arthritis,~* gouty arthropathy~* presence of neoplasm,~* allergy to shea nut oil production~* use of corticosteroids within 3 weeks prior to baseline and throughout the study~* use of anti-inflammatory agents 3 weeks prior to baseline and for the duration of the study,~* history of trauma associated with the signal joint,~* liver function tests greater than twice the upper limit of normal at baseline~* history of alcohol or substance abuse.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Shea nut oil (Type: EXPERIMENTAL): 100% shea nut oil extract with 75% triterpene esters. Daily dosage is three 750 mg soft gel capsules (2250 mg/per day) taken in the morning for 3 months
- Placebo (Type: PLACEBO_COMPARATOR): placebo which comprised 100% canola oil or starch mixed soybean oil

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Randomised Controlled Trial of the Efficacy of Acupuncture Versus Placebo on the Caesarean Section Rate in Case of Cervical Dystocia in Full-term Pregnancy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Aged ≥ 18 years~* Signed informed consent~* Woman carrying one foetus only~* at 37 weeks (+/- 2 days) of amenorrhea~* Without contraindication to vaginal delivery~Exclusion Criteria:~* Prior history of caesarean section~* Non-cephalic presentation~* Fetal macrosomia~* Multiple pregnancy~* Chronic fetal hypoxia~* Placenta praevia~* Risk of neonatal contamination

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- acupuncture (Type: EXPERIMENTAL): The first session of acupuncture treatment will be performed at the inclusion visit, 2 additional acupuncture sessions will be scheduled as 1 session per week for the next 2 weeks.~One or more additional session will be performed in the delivery room.
- Sham acupuncture (Type: SHAM_COMPARATOR): The same as active arm but with sham needles.
- control group (Type: NO_INTERVENTION): Standard care, no acupuncture session.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Multicentric Study Comparison Between Erythropoietin and Erythropoietin Associated to Differentiating Therapy With Acid 13-cis-retinoic and Dihydroxyvitamin D3 in Myelodysplastic Syndromes Without Excess of Blasts

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age higher than 18;~2. Confirmed diagnosis by osseous biopsy and bone marrow cyto-morphologic counts of blast cells, of Myelodysplastic syndrome without excess of blasts: refractary anemia, refractary anemia with rings sideroblasts, refractary citopenya with multilineage dysplasia,  refractary citopenya with multilineage dysplasia and rings sideroblasts or 5q-syndrome without excess of blasts based on WHO classification (appendix).~3. Low or intermediate-1 IPSS (appendix).~4. Hb \< 11g/dl.~5. rEPO serum level \< 500mU/L.~6. Women in menopause from at least one year.~7. Informed consent~Exclusion Criteria:~1. Myelodisplastic syndrome with excess of blasts (RAEB).~2. IPSS score intermediate-2 or high (appendix).~3. Forecasted allogeneic bone marrow transplant within 1 year after diagnosis(patients younger than 60 years, transfusion dependents or with serious leuko/thrombocytopenia and HLA compatible family donor).Considering the time needed to perform this procedure, the indication of a transplant from non-consanguineous donor has no contraindication to the inclusion in this protocol of the response to rEPO therapy ± differentiating therapy.~4. Renal failure with creatininemia value greater than 3 times the normal limit.~5. Chronic hepatophaty with bilirubinemia value greater than 3 times the normal limit and/or AST or ALT or ALP values greater than 5 times the normal limit.~6. Presence of second tumor or other serious pathology with life expectancy lower than one year.~7. Presence of neurologic or psychiatric pathologies that make the patient unreliable in the acquisition of drugs.~8. Allergy/intolerance known to use drugs.~9. Pregnant women.~10. Women of childbearing age or in menopause from less than one year.~11. Age \< 18 years old.~12. HIV positive.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Infusion A: rEPO (Type: EXPERIMENTAL): rEPO for 4 mounths consequently
- Infusion B combined r-EPO (Type: EXPERIMENTAL): rEPO in association with acid 13-cis-retinoic acid and Dihydroxyvitamin D3 for 4 mounths consequently

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Role Functioning Changes NOS

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 to 26 years~2. Individuals seeking treatment for psychiatric symptoms in a clinical care setting~3. Able to provide informed consent (age 18-26)~4. Subjects must consent to a review of the medical records in order to track changes in clinical symptoms~5. Fluent in English~Exclusion Criteria:~1. Adults unable to consent~2. Individuals who have not reached the age of 18~3. Pregnant women~4. Prisoners.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 26 Years
- Healthy Volunteers: f

Study Arms:
- Treatment seeking patients (Type: None): Patients between 18 and 26 who arrive seeing treatment for new-onset mental health symptoms. They will receive treatment as usual, while being assessed overt he course of one year for changes in role functioning.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of orBec® With Prednisone Therapy in the Treatment of Patients With Graft Versus Host Disease (GVHD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Receipt of allogeneic hematopoietic cell transplant~* Diagnosis of GI graft vs. host disease (GVHD)~* No GI infection~* Must be able to swallow tablets~* Must be able to read and understand informed consent~* Adequate birth control methods for the duration of the study~Exclusion Criteria:~* Significant Skin GVHD~* Liver GVHD~* Persistent vomiting~* HIV positive~* Pregnancy/lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- orBec® (Type: EXPERIMENTAL): Investigational drug
- Placebo (Type: PLACEBO_COMPARATOR): Control

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Antineoplaston Therapy in Treating Patients With Recurrent or Stage IV Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed recurrent or stage IV squamous cell lung cancer unlikely to have a curative response to existing standard regimens~* Measurable disease by MRI or CT scan~  * At least 2 cm in diameter~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Karnofsky 60-100%~Life expectancy:~* At least 2 months~Hematopoietic:~* WBC at least 2,000/mm3~* Platelet count at least 50,000/mm3~Hepatic:~* Bilirubin no greater than 2.5 mg/dL~* SGOT/SGPT no greater than 5 times upper limit of normal~* No hepatic failure~Renal:~* Creatinine no greater than 2.5 mg/dL~* No renal insufficiency~* No history of renal conditions that contraindicate high dosages of sodium~Cardiovascular:~* No severe heart disease~* No uncontrolled hypertension~* No history of congestive heart failure~* No history of other cardiovascular conditions that contraindicate high dosages of sodium~Pulmonary:~* No severe lung disease (e.g., chronic obstructive pulmonary disease)~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 4 weeks after study~* No serious active infections~* No other serious concurrent disease~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 4 weeks since prior immunotherapy and recovered~* No concurrent immunomodulating agents~Chemotherapy:~* At least 4 weeks since prior chemotherapy (6 weeks since nitrosoureas) and recovered~* No concurrent antineoplastic agents~Endocrine therapy:~* Concurrent corticosteroids allowed~Radiotherapy:~* At least 8 weeks since prior radiotherapy and recovered~Surgery:~* Recovered from prior surgery~Other:~* No prior antineoplaston therapy~* Prior cytodifferentiating agent allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Antineoplaston therapy (Type: EXPERIMENTAL): Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Superior Labral Tear From Anterior to Posterior (SLAP) Repair Versus Biceps Tenodesis for SLAP Tears in the Shoulder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Primary isolated SLAP tear, confirmed on MRI~Exclusion Criteria:~* Concomitant procedure needed such as a labral repair, rotator cuff repair or distal clavicle excision.~* Revision Surgery~* Previous shoulder surgery~* Major medical illness~* Inability to speak or read English

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- SLAP Repair (Type: EXPERIMENTAL): Patient will receive SLAP repair for their SLAP tear.
- Biceps Tenodesis Repair (Type: EXPERIMENTAL): Patient will receive biceps tenodesis repair for their SLAP tear.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Increasing Use of Continuous Glucose Monitors in Publicly-insured Youth With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* type 1 diabetes for more than 6 months~* on insulin pump or multiple daily injections without plans to change modality in next 6 months~* insured by CCS or Medi-Cal~* receiving care at Lucile Packard Children's Hospital or Stanford Children's Health outpatient clinics~* English or Spanish-speaking~Exclusion Criteria:~* major illness or condition that may alter glucose control or ability to complete the study including pregnancy, cystic fibrosis, cancer, liver disease, history of transplant, or hemoglobinopathy~* current oral glucocorticoid use~* prior use of a CGM system~* hemoglobin A1C \<7.5% or \>12%~* no wireless internet access

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 19 Years
- Healthy Volunteers: f

Study Arms:
- Gamification (Type: EXPERIMENTAL): Use of continuous glucose monitor (Dexcom G5) with proactive intervention and incentives for time in use.
- Standard care (Type: ACTIVE_COMPARATOR): Use of continuous glucose monitor (Dexcom G5) per usual care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pemetrexed Disodium and Cisplatin Before or After Surgery in Treating Patients With Stage IB or Stage II Non-Small Cell Lung Cancer That Can be Removed by Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Pathologically confirmed non-small cell lung cancer (NSCLC)~  * Stage IB or II disease~* Resectable disease~* At least 1 measurable lesion~* No mediastinal involvement by mediastinoscopy and/or positron emission tomography with fludeoxyglucose F 18 scan~* No evidence of metastatic disease~PATIENT CHARACTERISTICS:~* WHO performance status 0-2~* Absolute neutrophil count \> 1,500/mm³~* Platelet count \> 100,000/mm³~* Hemoglobin \> 10 g/dL~* Creatinine clearance ≥ 60 mL/min~* Bilirubin ≤ 1.5 times upper limit of normal (ULN)~* Alkaline phosphatase ≤ 3.0 times ULN~* AST and ALT ≤ 3.0 times ULN~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No other malignant disease, except for the following:~  * Basocellular carcinoma of the skin~ * Adequately treated carcinoma in situ of the cervix~ * Low-grade prostate cancer~ * Other cancer for which the patient has been disease-free for ≥ 5 years~* No congestive heart failure or angina pectoris unless medically controlled~* No myocardial infarction within the past 6 months~* No uncontrolled hypertension or arrhythmia~* No active uncontrolled infection requiring antibiotics~* No illness or medical condition that would preclude study participation~* No pre-existing motor or sensory neurotoxicity ≥ grade 2~PRIOR CONCURRENT THERAPY:~* No prior surgery for NSCLC~* No prior or other concurrent chemotherapy for NSCLC~* No prior or concurrent radiotherapy for NSCLC~* No concurrent immunotherapy~* No concurrent targeted agents~* No concurrent hormonal cancer therapy~* No concurrent routine colony-stimulating factor (e.g., prophylactic filgrastim \[G-CSF\])~* No aspirin or nonsteroidal anti-inflammatory drugs within 5 days before or after chemotherapy~* No other concurrent experimental treatments~* No other concurrent anticancer treatments

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility of Check-Cap's P1 Capsule System Screening

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female between 40 and 75 years of age.~* Subject is generally in good health.~* Subject is ready to undergo FOBT or FIT and Colonoscopy.~* Subject agrees to sign the informed consent.~Exclusion Criteria:~* Subject has any known Gastro Intestinal \[GI\] related symptoms, complaints or GI diseases.~* Subject is contraindicated from performing colon cleansing (bowel prep.)~* Subject has cancer or other life threatening diseases or conditions.~* Female subject is pregnant.~* Subject underwent any abdominal surgery.~* Morbid Obese (BMI \> 40) subject.~* Subject has known drug abuse or alcoholism problem.~* Subject is under custodial care.~* Subject is currently or will be participating in other clinical study within 30 days prior to Check-Cap procedure

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- P1 capsule and screening Cscopy (Type: OTHER): Male and female patients older than 40 and younger than 75 years old who volunteer for the experiment and qualify with the inclusion / Exclusion criteria.~The P1 Check-Cap capsule will be ingested by all participants. After the Capsule test, they will be referred for optical colonoscopy as part of the study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Nifedipine or Nifedipine Plus Indomethacin for Treatment of Acute Preterm Labor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* We will include pregnant women between 22 0/7 to 31 6/7 weeks gestation who present with regular uterine contractions defined as at least one contraction every 10 minutes for 30 minutes with at least one of the following:~* cervical change of at least 1 cm or~* cervical dilation of 2 cm at the time of initial exam or~* positive fetal fibronectin and transvaginal cervical length \<2.5 cm~Exclusion Criteria:~* We will exclude pregnant women with any contraindication to tocolysis:~* clinical chorioamnionitis (defined as a temperature of \>100.4 F and any of the following: fundal tenderness, maternal tachycardia, fetal tachycardia or purulent vaginal discharge)~* non reassuring fetal heart tones~* suspected placental abruption~* preterm premature rupture of membranes~* prior tocolytic treatment during the past 48 hours~* known adverse effect to indomethacin or nifedipine~* already receiving nifedipine for chronic hypertension

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Nifedipine (Type: ACTIVE_COMPARATOR): Participants will receive nifedipine 10 mg orally every 20 minutes for 3 doses, then nifedipine 10 mg every 6 hours for a total of 48 hours.
- Nifedipine plus Indomethacin (Type: ACTIVE_COMPARATOR): Participants will receive will receive nifedipine 10 mg orally every 20 minutes for 3 doses, then nifedipine 10 mg every 6 hours for a total of 48 hours, as well as indomethacin 100 mg orally, then indomethacin 50 mg orally every 6 hours for a total of 48 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Spectacle Tints and Thin-Films for Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must meet the International Headache Society criteria for chronic migraine (International Classification of Headache Disorders, 3rd edition (Headache Classification Committee of the International Headache Society, 2013). All subjects must be between the ages of 18 and 60 years-old.~To be included in the study, in the best judgment of the investigator, subjects must be stable on their current migraine treatment regimen. Stability is defined as no major changes in therapy contemplated within the next 4 months.~Exclusion Criteria:~* Subjects with other light sensitive conditions, such as iritis and blepharospasm, will be excluded. Subjects with best-corrected visual acuity less than 20/40 will be excluded. Subjects with diseases of the retina, such as diabetic retinopathy and macular degeneration will be excluded. Subjects using medications known to affect the eye will be excluded (e.g. chloroquine, hydroxychloroquine, ethambutol, amiodarone). Due to constraints on the manufacture and mounting of study lenses into study frames, the study must exclude subjects who are very nearsighted (more than 4 diopters), subjects who are very farsighted (more than 2 diopters), and subjects who have more than 2.5 diopters of astigmatism.~Because of the cyclical effects of botulinum toxin injections and other nerve blocks, patients undergoing these treatments will be excluded. Subjects must not have had any injections or blocks within 4 months of enrollment and should not receive any further blocks until they exit the study.~Subjects with continuous daily headache (a headache frequency of 100%) will be excluded. Subjects who do not have a headache frequency of at least 50% will be excluded.~Subjects with medication overuse headache will be excluded. A patient with a history of medication overuse who has not overused abortive medications for the past 4 months can be included.~Subjects who abuse alcohol or use illicit drugs will be excluded. Subjects considered to be from vulnerable populations will be excluded, including pregnant women, prisoners, subject who are mentally disabled, subjects with cognitive or decisional impairment, and wards of the state

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Gray tinted spectacle lenses (Type: ACTIVE_COMPARATOR): Subjects in this arm will be asked to wear a neutral gray tint that blocks all wavelengths equally
- Thin-Film spectacle lenses (Type: EXPERIMENTAL): Subjects in this arm well be asked to wear a thin-film coating that specifically blocks 480-nm wavelength

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues